Search
Abstract & travel grant submission
Abstract submission is closed
Abstract procedurePlease note that the submission of an abstract constitutes a formal commitment by the presenting author to present the abstract (if accepted) orally or as a poster in the session at the time assigned by the…
Choose your membership
Wherever you are in the world, you can join our vibrant community and benefit from our rigorous resources and career-enhancing opportunities.
Read moreChairs and members
Chair (2024–2027 term)Igor Aurer (education and scientific meetings co-lead) – University Hospital Centre Zagreb, University of Zagreb and KroHem, Croatia
Co-chair (2024–2027 term)Martin Dreyling (guidelines lead) – University Hospital Grosshadern, Ludwig Maximilian University and GLA, Germany
SWG Executive Board members (2024–2027 term)
Kim Linton (scientific secretary) –…
Abstract & Clinical Case Submission and Travel Grant
Abstract and clinical case procedureAbstract submission is closed
The official abstract submission closed on August 1, 2023 (23:59).
Travel Grants
Application for a travel grant closed on August 29
Travel grants are intended to support young investigators; therefore, applicants should be 36 years of age or young and are reserved for applicants from upper-middle, lower-middle, and low-income countries.
EHA-SWG Scientific Meeting on Red Cell and Iron Metabolism Defects: From Basic Science to Clinical Case Application
Dates: October 12-14, 2023
Location: Budapest, Hungary
Chairs: A Taher & A Iolascon
Collaborating SWG: EHA Specialized Working Group on Red Cells and Iron
Registration is closed
RegistrationRegistration is closed. Visit this page for more information.
Publications
Ruxolitinib for the management of myelofibrosis: Results of an international physician survey. Ellis MH, Koren-Michowitz M, Lavi N, Vannucchi AM, Mesa R, Harrison CN. Leuk Res. 2017 Oct;61:6-9. doi: 10. 1016/j. leukres. 2017. 08. 002.
Read morePublications
For the subgroup Rare hereditary blood cancers:
GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- »